Wisevoter
Houston

Eos to Present PTC-2105 Mouse Data at SCWD

Eos SENOLYTIX will present pre-clinical mouse results for its compound PTC-2105 at the 19th SCWD conference in Washington, D.C.

Updated on Nov. 9, 2026 in Weight Loss

Clear glass beakers and a rack of sealed vials on a clean stainless laboratory bench under soft daylight.
Eos SENOLYTIX will present pre-clinical mouse data on its compound PTC-2105 at the 19th SCWD conference in Washington, D.C., in December 2026. AI Illustration. Upload story photo >

Live Poll

Would you worry about losing muscle while taking a GLP-1 weight-loss drug?

Eos SENOLYTIX, based in Houston, Texas, announced it will present pre-clinical mouse data on its investigational compound PTC-2105 at the 19th SCWD conference, scheduled for December 2026. The presentation was upgraded to a plenary session in the Rapid Fire Abstract Session.

Why it matters

Lean mass makes up 15-40% of the weight lost with GLP-1 therapies, raising concerns about sarcopenia and frailty. The mouse data examines whether PTC-2105 can preserve lean mass alongside semaglutide, a question relevant to weight-loss treatment in Houston and beyond.

Pre-clinical mouse data show PTC-2105 monotherapy shifted terminal lean-mass trend from decline to net gain (+0.005 g/wk versus -0.002 g/wk for saline), while semaglutide alone produced the steepest decline (-0.055 g/wk). Whether these mouse findings translate to human patients has not been established.

The players

Eos SENOLYTIX

Eos SENOLYTIX is a Houston, Texas-based company developing geropeptide therapies, including the investigational compound PTC-2105.

Pulmatrix, Inc.

Pulmatrix, Inc. is a publicly traded biopharmaceutical company whose stockholders approved a merger with Eos SENOLYTIX.

The details

Eos SENOLYTIX will present the data in a plenary session at the 19th SCWD conference in Washington, D.C. The compound PTC-2105 is a once-weekly, subcutaneously injected geropeptide from the MitoXcel platform. Co-administration with semaglutide reduced late-life lean-mass loss relative to semaglutide alone.

Timeline

  1. Dec. 10-12, 2026: 19th SCWD conference in Washington, D.C.

  2. Dec. 11, 2026, 9:35 a.m. ET: Eos plenary presentation in the Rapid Fire Abstract Session.

  3. Oct. 26, 2026: Pulmatrix stockholders approved the proposed merger with Eos.

  4. Q4 2026: The merger is anticipated to close, subject to Nasdaq listing approval.

Roadmap

Semaglutide's rise has drawn attention to muscle loss accompanying fat loss, a concern now shaping how new weight-loss compounds are evaluated. PTC-2105 is being tested as a companion approach to that class rather than a replacement for it.

For people using GLP-1 medications, the findings point to lean-mass loss as a factor to monitor alongside fat loss. The data remain pre-clinical, so no change to current treatment is indicated.

The takeaway

Preserving lean mass during weight loss is an emerging research priority, particularly for older adults. Readers considering GLP-1 therapy may want to discuss muscle health with their clinicians.

What happens next

The merger between Eos SENOLYTIX and Pulmatrix is anticipated to close in the fourth quarter of 2026, after which the combined company's stock is expected to trade on Nasdaq as MTXL.

Further reading

Explore more Weight Loss coverage to see how muscle preservation fits into current treatment research.

More information

Review the merger materials on the Pulmatrix investor page.

Source note: This article includes information reported by The Manila times.

Live Poll

Would you worry about losing muscle while taking a GLP-1 weight-loss drug?